
Eric Santoni-Rugiu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3488641/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature, 1999, 401, 815-818.	27.8	269
2	Involvement of Myc Activity in a G 1 /S-Promoting Mechanism Parallel to the pRb/E2F Pathway. Molecular and Cellular Biology, 2000, 20, 3497-3509.	2.3	169
3	Transit-Amplifying Ductular (Oval) Cells and Their Hepatocytic Progeny Are Characterized by a Novel and Distinctive Expression of Delta-Like Protein/Preadipocyte Factor 1/Fetal Antigen 1. American Journal of Pathology, 2004, 164, 1347-1359.	3.8	129
4	Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. Cancers, 2019, 11, 923.	3.7	124
5	PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Annals of Oncology, 2012, 23, 2034-2042.	1.2	122
6	The Histone Methyltransferase and Putative Oncoprotein MMSET Is Overexpressed in a Large Variety of Human Tumors. Clinical Cancer Research, 2011, 17, 2919-2933.	7.0	118
7	Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 9577-9582.	7.1	112
8	Remarkable heterogeneity displayed by oval cells in rat and mouse models of stem cell–mediated liver regeneration. Hepatology, 2007, 45, 1462-1470.	7.3	106
9	Progenitor cells in liver regeneration: molecular responses controlling their activation and expansion. Apmis, 2005, 113, 876-902.	2.0	104
10	CRISPR/Cas9 Engineering of Adult Mouse Liver DemonstratesÂThat the Dnajb1–Prkaca Gene Fusion Is SufficientÂto Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma. Gastroenterology, 2017, 153, 1662-1673.e10.	1.3	86
11	In vivo infusion of growth factors enhances the mitogenic response of rat hepatic ductal (oval) cells after administration of 2-acetylaminofluorene. Hepatology, 1996, 23, 71-79.	7.3	76
12	Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution. Cancer Discovery, 2021, 11, 2456-2473.	9.4	74
13	Lipocalin 2 is protective against E. coli pneumonia. Respiratory Research, 2010, 11, 96.	3.6	73
14	p16INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesis. Oncogene, 1999, 18, 3930-3935.	5.9	68
15	Heterogeneity of Ductular Reactions in Adult Rat and Human Liver Revealed by Novel Expression of Deleted in Malignant Brain Tumor 1. American Journal of Pathology, 2002, 161, 1187-1198.	3.8	64
16	High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer. Npj Genomic Medicine, 2019, 4, 13.	3.8	63
17	ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Annals of Oncology, 2010, 21, 1817-1824.	1.2	62
18	MMSET Is Highly Expressed and Associated with Aggressiveness in Neuroblastoma. Cancer Research, 2011, 71, 4226-4235.	0.9	62

#	Article	IF	CITATIONS
19	Cancer predisposition in mice deficient for the metastasis-associated Mts1(S100A4) gene. Oncogene, 2004, 23, 3670-3680.	5.9	59
20	Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials. Clinical Cancer Research, 2019, 25, 1239-1247.	7.0	59
21	Diagnostic Potential of miR-126, miR-143, miR-145, and miR-652 in Malignant Pleural Mesothelioma. Journal of Molecular Diagnostics, 2014, 16, 418-430.	2.8	57
22	Acceleration of c-myc-Induced Hepatocarcinogenesis by Co-Expression of Transforming Growth Factor (TGF)-α in Transgenic Mice Is Associated with TGF-β1 Signaling Disruption. American Journal of Pathology, 1999, 154, 1693-1700.	3.8	52
23	Loss of miR-10a Activates Lpo and Collaborates with Activated Wnt Signaling in Inducing Intestinal Neoplasia in Female Mice. PLoS Genetics, 2013, 9, e1003913.	3.5	51
24	RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer, 2012, 75, 306-312.	2.0	43
25	Differential modulation of P-glycoprotein expression by dexamethasone and 3-methycholanthrene in rat hepatocyte primary cultures. Carcinogenesis, 1994, 15, 335-341.	2.8	42
26	The level of claudin-7 is reduced as an early event in colorectal carcinogenesis. BMC Cancer, 2011, 11, 65.	2.6	42
27	Class III β-Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized Trial. Clinical Cancer Research, 2011, 17, 5205-5214.	7.0	41
28	Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma. International Journal of Cancer, 2012, 131, E329-36.	5.1	41
29	Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat) Tj ETQq1 1 adenocarcinoma patient with acquired resistance to crizotinib: a case report. BMC Research Notes, 2013. 6, 489.	0.784314 1.4	4 rgBT /Overld 39
30	Transgenic mouse models in carcinogenesis: interaction of c-myc with transforming growth factor α and hepatocyte growth factor in hepatocarcinogenesis. British Journal of Clinical Pharmacology, 1996, 42, 43-52.	2.4	38
31	Conditional E2F1 activation in transgenic mice causes testicular atrophy and dysplasia mimicking human CIS. Oncogene, 2005, 24, 780-789.	5.9	38
32	Growth Inhibition and Induction of Apoptosis by HGF in Transformed Rat Liver Epithelial Cells. Biochemical and Biophysical Research Communications, 1997, 236, 396-401.	2.1	36
33	Concomitant driver mutations in advanced <i>EGFR</i> -mutated non-small-cell lung cancer and their impact on erlotinib treatment. Oncotarget, 2018, 9, 26195-26208.	1.8	35
34	IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. Lung Cancer, 2013, 79, 83-90.	2.0	33
35	Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival. Journal of Thoracic Oncology, 2012, 7, 249-256.	1.1	32
36	Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma. Anticancer Research, 2015, 35, 6223-9.	1.1	30

#	Article	IF	CITATIONS
37	Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer. European Journal of Cancer, 2013, 49, 2494-2503.	2.8	28
38	No Effect of NGAL/lipocalin-2 on Aggressiveness of Cancer in the MMTV-PyMT/FVB/N Mouse Model for Breast Cancer. PLoS ONE, 2012, 7, e39646.	2.5	27
39	Prdm5 suppresses ApcMin-driven intestinal adenomas and regulates monoacylglycerol lipase expression. Oncogene, 2014, 33, 3342-3350.	5.9	25
40	Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition. International Journal of Molecular Sciences, 2020, 21, 2847.	4.1	25
41	The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis. Pathology, 2021, 53, 446-453.	0.6	25
42	ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. European Journal of Cancer, 2010, 46, 1554-1562.	2.8	23
43	Ly6/uPAR-Related Protein C4.4A as a Marker of Solid Growth Pattern and Poor Prognosis in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2013, 8, 152-160.	1.1	21
44	A biomarker profile for predicting efficacy of cisplatin–vinorelbine therapy in malignant pleural mesothelioma. Cancer Chemotherapy and Pharmacology, 2012, 70, 743-754.	2.3	20
45	Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation. Lung Cancer, 2017, 113, 14-17.	2.0	20
46	E2F activity is essential for survival of Myc-overexpressing human cancer cells. Oncogene, 2002, 21, 6498-6509.	5.9	19
47	Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group. Lung Cancer, 2019, 127, 69-75.	2.0	19
48	The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas. Histopathology, 2012, 60, E96-105.	2.9	18
49	Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial. Annals of Oncology, 2013, 24, 309-314.	1.2	18
50	Personalized oncology: genomic screening in phase 1. Apmis, 2014, 122, 723-733.	2.0	18
51	Assessment of P-glycoprotein-dependent drug transport in isolated rat hepatocytes using rhodamine 123. Cell Biology and Toxicology, 1993, 9, 235-241.	5.3	16
52	Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma. International Journal of Cancer, 2012, 130, 2734-2739.	5.1	15
53	Molecular imaging in Libman-Sacks endocarditis. Infectious Diseases, 2015, 47, 263-266.	2.8	15
54	Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors. Oncotarget, 2018, 9, 32570-32579.	1.8	15

4

#	Article	IF	CITATIONS
55	Immune regulation by fibroblasts in tissue injury depends on uPARAP-mediated uptake of collectins. Journal of Cell Biology, 2019, 218, 333-349.	5.2	14
56	Magnetic resonance imaging with liver-specific contrast agent in primary amyloidosis and intrahepatic cholestasis. Acta Radiologica, 2007, 48, 145-149.	1.1	13
57	Application of cell-free DNA for genomic tumor profiling: a feasibility study. Oncotarget, 2019, 10, 1388-1398.	1.8	13
58	Comparison of Nuclear Grade, Necrosis, and Histologic Subtype Between Biopsy and Resection in Pleural Malignant Mesothelioma: An International Multi-Institutional Analysis. American Journal of Clinical Pathology, 2021, 156, 989-999.	0.7	12
59	Are differentially expressed micro <scp>RNA</scp> s useful in the diagnostics of malignant pleural mesothelioma?. Apmis, 2012, 120, 767-769.	2.0	11
60	Functional Proteomic Profiling of Triple-Negative Breast Cancer. Cells, 2021, 10, 2768.	4.1	10
61	Insulin-like growth factor receptor 1 mRNA expression as a prognostic marker in advanced non-small cell lung cancer. Anticancer Research, 2014, 34, 2991-6.	1.1	10
62	Interaction of c-myc with transforming growth factor α and hepatocyte growth factor in hepatocarcinogenesis. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997, 376, 221-234.	1.0	9
63	Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts. PLoS ONE, 2018, 13, e0194609.	2.5	9
64	Proliferation, apoptosis, and induction of hepatic transcription factors are characteristics of the early response of biliary epithelial (oval) cells to chemical carcinogens. Hepatology, 1996, 23, 62-70.	7.3	9
65	Safety Pharmacology, Toxicology and Pharmacokinetic Assessment of Human Gc Globulin (Vitamin D) Tj ETQq1	1 0,78431 2.5	4 rgBT /Overl
66	C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma. World Journal of Clinical Oncology, 2014, 5, 621.	2.3	8
67	Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery. Clinical Lung Cancer, 2021, 22, e528-e532.	2.6	8
68	Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic <i>ANK3-RET</i> Fusion in <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer. JCO Precision Oncology, 2022, , .	3.0	7
69	Hepatic Tumor Induction in c- Myc mono-transgenic and TGF- α/c-Myc double-transgenic Mice. Archives of Toxicology Supplement, 1997, 19, 359-366.	0.7	6
70	Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology, 2014, 73, 43-51.	2.3	5
71	Prevalence of Pathogenic Germline DICER1 Variants in Young Individuals Thyroidectomised Due to Goitre – A National Danish Cohort. Frontiers in Endocrinology, 2021, 12, 727970.	3.5	5
72	Use of TUBB3 for patient stratification and prognosis in lung cancer. Lung Cancer Management, 2015, 4, 97-110.	1.5	4

#	Article	IF	CITATIONS
73	Autoimmune pulmonary alveolar proteinosis in an adolescent successfully treated with inhaled rhGM-CSF (molgramostim). Respiratory Medicine Case Reports, 2018, 23, 167-169.	0.4	4
74	Ossifying thymoma associated with refractory myasthenia gravis. Apmis, 2010, 118, 334-336.	2.0	3
75	Differences in <scp>RRM</scp> 1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in nonâ€smallâ€cell lung cancer. Histopathology, 2014, 64, 412-420.	2.9	3
76	Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 131-137.	2.3	3
77	The Collagen Receptor uPARAP in Malignant Mesothelioma: A Potential Diagnostic Marker and Therapeutic Target. International Journal of Molecular Sciences, 2021, 22, 11452.	4.1	3
78	High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma. Anticancer Research, 2015, 35, 6731-8.	1.1	3
79	Treatment Algorithm for Advanced ALK-Rearranged NSCLC. Journal of Thoracic Oncology, 2020, 15, e156-e157.	1.1	2
80	Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma. International Journal of Molecular Sciences, 2021, 22, 12868.	4.1	2
81	Inducibility of gamma-glutamyltransferase by dexamethasone in rat liver: Relationship with the cytochrome P-450 content. Life Sciences, 1993, 52, 631-637.	4.3	1
82	Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 645-652.	2.5	1
83	Clinical outcomes provide new insights into transformation to small-cell lung cancer of pulmonary EGFR-mutant adenocarcinoma. Precision Cancer Medicine, 0, 2, 5-5.	1.8	1
84	Copenhagen prospective personalized oncology (CoPPO): Sequencing and array-based pipeline for selection of patients to phase 1 studies Journal of Clinical Oncology, 2014, 32, 11097-11097.	1.6	1
85	PP 88 C4.4A as a biomarker for poor prognosis in non-small cell lung cancer patients with adenocarcinomas. European Journal of Cancer, 2011, 47, S20.	2.8	Ο
86	Prognostic and Predictive Impact Of KI-67 Index in Neo-Adjuvant Chemotherapy Before Surgery in Non-Small Cell Lung Cancer. Annals of Oncology, 2012, 23, ix80.	1.2	0
87	MicroRNAs as potential biomarkers in malignant pleural mesothelioma. Current Biomarker Findings, 0, , 1.	0.4	0
88	NSCLC multiplex IHC diagnosis of small biopsies. Annals of Oncology, 2016, 27, vi405.	1.2	0
89	NSCLC - multiplex immunohistochemical staining for diagnosis in small biopsies. European Journal of Cancer, 2016, 61, S191-S192.	2.8	0
90	P3.01-007 Heterogeneous Resistance Mechanisms in Rebiopsies from EGFR-Mutated NSCLC: Transformation to SCLC; FGFR3 and T790M Mutations. Journal of Thoracic Oncology, 2017, 12, S2203.	1.1	0

#	Article	IF	CITATIONS
91	Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomized in a chemotherapy phase III trial Journal of Clinical Oncology, 2012, 30, 10617-10617.	1.6	0
92	Abstract 3556: Diagnostic potential of microRNAs (miRs) in malignant pleural mesothelioma (MPM) , 2013, , .		0
93	Versatile multigene expression biomarker for predicting clinical platinum sensitivity in non-small cell lung cancer (NSCLC) and ovarian cancer (OC) Journal of Clinical Oncology, 2015, 33, e18502-e18502.	1.6	Ο
94	Actionable targets in recurrent bile duct and pancreatic cancer in a prospective cohort of patients evaluated by whole exome sequencing and SNP array analysis Journal of Clinical Oncology, 2016, 34, e23256-e23256.	1.6	0
95	Prospective blinded evaluation predicting efficacy of adjuvant cisplatinum and vinorelbine by a multigene assay after radical surgery in non-small cell lung cancer Journal of Clinical Oncology, 2016, 34, e20007-e20007.	1.6	0
96	Dynamics of mutant BRAF V600E in free circulating DNA (fcDNA) of non-melanoma cancer patients (pts) in response to treatment with BRAF and MEK/EGFR inhibitors Journal of Clinical Oncology, 2016, 34, 11531-11531.	1.6	0